Les publications

Page en cours de mise à jour... Retrouvez ici les publications des équipes de recherche du CGO

Réseaux Appels à projets Actualités
430 publications
Année de publication :
Réseaux :

COVID-19 and people followed for breast cancer: French guidelines for clinical practice of Nice-St Paul de…

  • Ref: doi: 10.1016/j.bulcan.2020.03.008
  • Année de publication : 2020
  • Auteurs : Gligorov J, Bachelot T, Pierga JY, Antoine EC, Balleyguier C, Barranger E, Belkacemi Y, Bonnefoi H, Bidard FC, Ceugnart L, Classe JM, Cottu P, Coutant C, Cutuli B, Dalenc F, Darai E, Dieras V, Dohollou N, Giacchetti S, Goncalves A, Hardy-Bessard AC, Houvenaeghel G, Jacquin JP, Jacot W, Levy C, Mathelin C, Nisand I, Petit T, Petit T, Poncelet E, Rivera S, Rouzier R, Salmon R, Scotté F, Spano JP, Uzan C, Zelek L, Spielmann M, Penault-Llorca F, Namer M, Delaloge S
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma.

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer related to asbestos exposure. The tumor microenvironment content, particularly the presence of macrophages, was described as crucial for the development of the disease.

  • Ref: doi: 10.1136/jitc-2019-000182
  • Année de publication : 2020
  • Auteurs : Blondy T, d'Almeida SM, Briolay T, Tabiasco J, Meiller C, Chéné AL, Cellerin L, Deshayes S, Delneste Y, Fonteneau JF, Boisgerault N, Bennouna J, Grégoire M, Jean D, Blanquart C
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

EPA and DHA Fatty Acids Induce a Remodeling of Tumor Vasculature and Potentiate Docetaxel Activity.

n-3 long chain Polyunsaturated Fatty Acids (n-3 LCPUFA) have been shown to improve the efficacy of conventional chemotherapies used for breast cancer treatment. In addition to their reported ability to increase the chemosensitivity of cancer cells, we hypothesized that n-3 LCPUFA could induce a remodeling of the vascular network in mammary tumors.

  • Ref: doi: 10.3390/ijms21144965
  • Année de publication : 2020
  • Auteurs : Goupille C, Vibet S, Frank PG, Mahéo K
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms.

Inflammatory cytokines play a major role in myeloproliferative neoplasms (MPNs) as regulators of the MPN clone and as mediators of clinical symptoms and complications. Firstly, we investigated the effect of JAK2V617F on 42 molecules linked to inflammation.

  • Ref: doi: 10.3390/cancers12092446
  • Année de publication : 2020
  • Auteurs : Allain-Maillet S, Bosseboeuf A, Mennesson N, Bostoën M, Dufeu L, Choi EH, Cleyrat C, Mansier O, Lippert E, Le Bris Y, Gombert JM, Girodon F, Pettazzoni M, Bigot-Corbel E, Hermouet S
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients.

Previous studies showed that monoclonal immunoglobulins G (IgGs) of « monoclonal gammopathy of undetermined significance » (MGUS) and myeloma were hyposialylated, thus presumably pro-inflammatory, and for about half of patients, the target of the monoclonal IgG was either a virus-Epstein…

  • Ref: doi: 10.3389/fimmu.2020.00854
  • Année de publication : 2020
  • Auteurs : Bosseboeuf A, Seillier C, Mennesson N, Allain-Maillet S, Fourny M, Tallet A, Piver E, Lehours P, Mégraud F, Berthelot L, Harb J, Bigot-Corbel E, Hermouet S
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr…

: Chronic stimulation by infectious or self-antigens initiates subsets of monoclonal gammopathies of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or multiple myeloma (MM). Recently, glucosylsphingosine (GlcSph) was reported to be the target of one third of monoclonal immunoglobulins (Igs).

  • Ref: doi: 10.3390/cancers12051254
  • Année de publication : 2020
  • Auteurs : Bosseboeuf A, Mennesson N, Allain-Maillet S, Tallet A, Piver E, Decaux O, Moreau C, Moreau P, Lehours P, Mégraud F, Salle V, Bigot-Corbel E, Harb J, Hermouet S
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients.

n BRAF wild type advanced melanoma, immune checkpoint blockers such as anti-PD1 (anti-programmed cell death 1) are usually continued beyond progression for a hypothetical rare further response. Chemotherapy as a second-line option is considered ineffective by many practitioners based on historical data.

  • Ref: doi: 10.1097/MD.0000000000021329
  • Année de publication : 2020
  • Auteurs : Saint-Jean M, Fronteau C, Peuvrel L, Khammari A, Varey E, Quéreux G, Dréno B
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with…

We sought to identify patient subgroups with distinct postprogression overall survival (ppOS) outcomes and investigate the impact of original treatment assignment and initial postprogression treatment (ppRx) on ppOS.

  • Ref: doi: 10.1186/s12967-020-02458-x
  • Année de publication : 2020
  • Auteurs : Ascierto PA, Ribas A, Larkin J, McArthur GA, Lewis KD, Hauschild A, Flaherty KT, McKenna E, Zhu Q, Mun Y, Dréno B
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with…

This study investigated the efficacy and safety of pimasertib (MEK1/MEK2 inhibitor) versus dacarbazine (DTIC) in patients with untreated NRAS-mutated melanoma.

  • Ref: doi: 10.3390/ijms21145025
  • Année de publication : 2020
  • Auteurs : Lebbé C, Dutriaux C, Lesimple T, Kruit W, Kerger J, Thomas L, Guillot B, Braud F, Garbe C, Grob JJ, Loquai C, Ferraresi V, Robert C, Vasey P, Conry R, Isaacs R, Espinosa E, Schueler A, Massimini G, Dréno B
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication